The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
#SOHO2024: Aggressive B-cell non-Hodgkin lymphoma
To update you on the exciting content presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, we have collated our social media coverage. Catch up on our live social media coverage relating to aggressive B-cell non-Hodgkin lymphoma below.
CONGRESS | #SOHO2024 | POSTER@DrRaulCordoba @Hospital_FJD presents long-term data from the phase I/II EPCORE NHL-2 trial of epcoritamab + GemOx in a larger cohort of pts with transplant-ineligible R/R #DLBCL, with a focus on complete responders and 2L patients. N=103, ORR were… pic.twitter.com/wb475oUBDC
— Lymphoma Hub (@lymphomahub) September 9, 2024
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 9, 2024
Frederick Locke, @MoffittNews, talks about CAR T-cell therapy after CAR T-cell therapy for DLBCL. He discusses factors affecting its effectiveness such as immune status within the tumor cells, tumor IFN signaling, suppressive features, target, and the CAR… pic.twitter.com/z57tzjPTIR
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 6, 2024
Christopher Yasenchak, Willamette Valley Cancer Institute, shares results from the phase III ECHELON-3 study of brentuximab vedotin in combination with len and rituximab for R/R DLBCL.
Median PFS 4.2 mo, OS 13.8 mo, ORR 64%, CR 40%, AEs were managed with dose… pic.twitter.com/vQ6hK7km2A
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 6, 2024
Jason Westin @Lymphoma_Doc @MDAndersonNews shares data from the phase Ib trial of GOLCA+R-CHOP as 1L therapy in aggressive B-cell #lymphoma. ORR 0.2mg 82% and 0.4mg 88%, uMRD 0.2mg 73% and 0.4mg 90%, median DoR NR in either group, 12-mo PFS 0.4mg 85%, 120-mo… pic.twitter.com/uPhpTo9lZX
CONGRESS | #SOHO2024@AstridPavlovsky, Fundaleu, Buenos Aires, discusses accessing novel therapies for aggressive lymphoma; concluding that while there are significant advances in the management of lymphomas, there remains discrepancies in access to novel therapies and clinical… pic.twitter.com/DDEJpuA4il
— Lymphoma Hub (@lymphomahub) September 6, 2024
CONGRESS | #SOHO2024@gilles_salles @MSKCancerCenter discusses how to sequence therapies in R/R DLBCL, with the aim to optimize the chance of cure; concluding with a look to the future landscape and the possibility of achieving a cure amongst a substantial fraction of patients.… pic.twitter.com/wqZN2SS7sd
— Lymphoma Hub (@lymphomahub) September 6, 2024
CONGRESS | POSTER | #SOHO2024 |
— Lymphoma Hub (@lymphomahub) September 4, 2024
Ning Dong @NingDong9 presents single center experience of SoC epcoritamab for R/R #LBCL (N=26). In this heavily pretreated population, the CR rate was 18.9% at median follow-up of 4 months, with PR in 31.8%. #lymphoma #lymsm #MedicalCongress pic.twitter.com/bPZ8sIw2zt
CONGRESS | POSTER | #SOHO2024 | Yasmin Karimi @Yhkarimi presents extended follow-up data beyond 2.5 years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained in CR at 30… pic.twitter.com/mkTvkPIput
— Lymphoma Hub (@lymphomahub) September 4, 2024
CONGRESS | POSTER | #SOHO2024 | Martin Hutchings @DocHutchings presents extended follow-up from a pivotal phase II study of glofitamab monotherapy in pts with R/R #DLBCL (N=155) and subgroup analysis in pts with prior CAR-T cell therapy (N=52). Overall ORR was 52% with overall CR… pic.twitter.com/m5DMB3SQwN
— Lymphoma Hub (@lymphomahub) September 4, 2024
CONGRESS | POSTER | #SOHO2024 | Daniel Kerr presents first results from the phase Ib/II EPCORE NHL-5 study investigating subcutaneous epcoritamab + pola-R-CHP as 1L treatment for #DLBCL (N=37). The ORR was 100% with CR 89%, demonstrating that epcoritamab can be combined with 1L… pic.twitter.com/9hGxqQxpNt
— Lymphoma Hub (@lymphomahub) September 4, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content